Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
trifluridine + tipiracil + oxaliplatin + sintilimab
- Development stage
- Unknown
- Lead developer
- Renji Hospital
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This combination regimen is a chemo-immunotherapy approach being evaluated for the first-line treatment of advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma. It consists of trifluridine/tipiracil (TAS-102), an oral nucleoside-based cytotoxic agent; oxaliplatin, a platinum-based chemotherapy; and sintilimab, a recombinant humanized anti-PD-1 monoclonal antibody. Trifluridine is phosphorylated into a cytotoxic form that incorporates into DNA, while tipiracil inhibits its degradation by thymidine phosphorylase, thereby increasing systemic exposure. Oxaliplatin induces DNA cross-linking, leading to apoptosis and synergistic cytotoxic effects. Sintilimab blocks the PD-1/PD-L1 pathway, reinvigorating the anti-tumor immune response. The regimen is primarily being studied in investigator-initiated trials led by Renji Hospital, Shanghai Jiao Tong University School of Medicine.
- Brand names
- Lonsurf
- Other names
- TAS-102 + oxaliplatin + sintilimab
02
Targets
DNATYMP (Thymidine phosphorylase)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on trifluridine + tipiracil + oxaliplatin + sintilimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on trifluridine + tipiracil + oxaliplatin + sintilimab.